About the book
Umbilical cord blood (UCB) and umbilical cord tissue (UCT) have been worldwide stored cryopreserved in private and public cord blood and tissue banks in order to obtain hematopoietic (HSCs) and mesenchymal stem cells (MSCs) to be used in several clinical applications, most of them still under study in pre-clinical and clinical trials or even in in vitro testing. Deep knowledge of the regulatory issues is crucial for the implementation and development of umbilical cord blood and umbilical cord tissue banks where the quality of the samples is of the most importance. The UCT and UCB have been used in several clinical trials concerning a wide range of pathologies and diseases that can be daily consulted.
Furthermore, Advanced Therapy Medicinal Products (ATMPs) derived from UCB and UCT, from clinical translation, will bring exciting studies and new data for stem cells therapies, gene therapy, and gene editing, and immunotherapy promoting the Regenerative Medicine. UCB and UCT will probably become important in Regenerative Medicine therapies, presenting unique challenges related to product testing, scientific protocols, product quality and specifications, performance characteristics, and compliance criteria. This field of knowledge implies a multidisciplinary team where pre-clinical trials using appropriate animal models can also allow the application of cell-based therapies in Veterinary Medicine working in a One Health approach.